Paul Hastings Advised Keensight Capital in the Combination of Biovian and 3P Biopharmaceuticals to Create 3PBIOVIAN

Paul Hastings (Europe) LLP advised Keensight Capital in the combination of Biovian and 3P Biopharmaceuticals, two leading biologics Contract Development and Manufacturing Organizations (CDMOs), to establish 3PBIOVIAN, a new pan-european leader in their field.

Corporate partner Olivier Deren led the Paul Hastings team, which also included partner Allard de Waal, of counsel Charlotte Dupont, and associates Amandine Guignard and Capucine Chareton.

Law firms Strelia (Vanessa Schmitt, partner, and Giada Mognol, associate), Garrigues (Laura Munoz, partner, Elisabet Terradellas and Sandra Velaz, associates) and Castrén & Snellman (Karlo Siirala, partner and Jussi Mäkikangas, associate) were respectively involved in the Luxembourg, Spanish and Finnish legal aspects of this transaction.

More details about the transaction can be found here.

About Paul Hastings

With widely recognized elite teams in finance, mergers & acquisitions, private equity, restructuring and special situations, litigation, employment, and real estate, Paul Hastings is a premier law firm providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers, and corporations.